Elmore, Leisha C.
Kuerer, Henry M.
Barcenas, Carlos H.
Smith, Benjamin D.
Miggins, Makesha V.
Lucci, Anthony
Caudle, Abigail S.
Meric-Bernstam, Funda
Hunt, Kelly K.
Teshome, Mediget http://orcid.org/0000-0001-8632-0256
Article History
Received: 22 April 2021
Accepted: 20 May 2021
First Online: 10 July 2021
Disclosures
: Benjamin Smith has received prior research funding from Varian Medical Systems, and has current royalty and equity interest in Oncora Medical. Funda Meric-Bernstam is a consultant for AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd, Genentech Inc., IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Seattle Genetics Inc., Tyra Biosciences, Xencor, and Zymeworks, and is a member of the Advisory Committee for Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, and Zentalis. She has also undertaken sponsored research for Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd, Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical (formerly Millennium Pharmaceutical), Novartis, Puma Biotechnology Inc., and Taiho Pharmaceutical Co., and has received honoraria from Chugai Biopharmaceuticals. Kelly Hunt is a member of the Medical Advisory Board of Armada Health and Merck & Co., and has received research funding to her institution from Cairn Surgical, Eli Lilly and Company, Lumicell, and OncoNano Medicine. Leisha C. Elmore, Henry M. Kuerer, Carlos H. Barcenas, Makesha V. Miggins, Anthony Lucci, Abigail S. Caudle, and Mediget Teshome have no conflicts of interest to declare.